Home › Research › Risk factors
Melatonin for Sleep Disorders and Cognition in Dementia
Jing Xu, Li-Ling Wang, Eric B. Dammer, Chun-Bo Li, Gang Xu, Sheng-Di Chen, Gang Wang. American Journal of Alzheimer's Disease & Other Dementias®, 2015-01-22
Topic: Drug trials: efficacy and safety
The current review aims to examine melatonin therapy for both sleep disturbances and cognitive function in dementia. We searched all randomized controlled trials published in Medline, Embase, the Cochrane Library, China National Knowledge Infrastructure, the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register, and Clinical Trials.gov . The grading of recommendations assessment, development and evaluation framework was used to assess the quality of evidence. Seven studies were included (n = 520). Treated participants showed prolonged total sleep time (TST) by 24.36 minutes ( P = .02). Sleep efficacy (SE) was marginally improved ( P = .07). This effect was stronger under a longer intervention period lasting more than 4 weeks ( P = .02). Conversely, cognitive function did not change significantly. Additionally, there was no report of severe adverse events. Given the current studies, we conclude that melatonin therapy may be effective in improving SE and prolonging TST in patients with dementia; however, there is no evidence that this improvement impacts cognitive function.
Key findings
- Conversely, cognitive function did not change significantly.
- Given the current studies, we conclude that melatonin therapy may be effective in improving SE and prolonging TST in patients with dementia; however, there is no evidence that this improvement impacts cognitive function.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Participants520
- Evidence strengthHigh
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 29 of the 56 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (American Journal of Alzheimer's Disease & Other Dementias®) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 520 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 29 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 29 of the 56 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Xu, J., Wang, L.-L., Dammer, E. B., Li, C.-B., Xu, G., Chen, S.-D., et al. (2015). Melatonin for Sleep Disorders and Cognition in Dementia. American Journal of Alzheimer's Disease & Other Dementias®. https://doi.org/10.1177/1533317514568005
Vancouver
Xu J, Wang L.-L, Dammer EB, Li C.-B, Xu G, Chen S.-D, et al. Melatonin for Sleep Disorders and Cognition in Dementia. American Journal of Alzheimer's Disease & Other Dementias®. 2015. doi:10.1177/1533317514568005.
BibTeX
@article{xu2015-6572f8e9,
author = {Xu, Jing and Wang, Li-Ling and Dammer, Eric B. and Li, Chun-Bo and Xu, Gang and Chen, Sheng-Di and Wang, Gang},
title = {{Melatonin for Sleep Disorders and Cognition in Dementia}},
journal = {American Journal of Alzheimer's Disease \& Other Dementias®},
year = {2015},
doi = {10.1177/1533317514568005},
url = {https://doi.org/10.1177/1533317514568005}
}
Related studies in Risk factors
Also tagged “apnea”
196 studies in the library carry the topic tag “apnea”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 196 tagged studies.